NecstGen

We're #hiring a new Senior QA Specialist (GMP Environment) in Leiden, South Holland. Apply today or share this post with your network.

We're #hiring a new Environment Monitoring (QC) Technician in Leiden, South Holland. Apply today or share this post with your network.

NecstGen is delighted to host a CGT Circle event on October 16th at our site in Leiden supporting The CGT Circle's mission to harness the collective power and experience of women in the field of Cell and Gene Therapy. Join us for an exceptional afternoon with brilliant speakers sharing insights on their career, lessons learned, and valuable advice and connect over networking drinks.    Join us on a journey into inspiring presentations from: - Rachel Abbott, CEO, Pan Cancer T - Ester Weijers, CEO, NTrans Technologies BV - Françoise Carlotti, Associate Professor and Head of the Islet Research Lab, Leiden University Medical Center - Maria Gomes Fernandes, PhD, Head of Cell & Tissue Sciences, Meatable We'll close with an engaging session on Communication led by Veronique van de Sande. This is an opportunity to refine your communication skills, crucial for leadership, and career growth in the field.   Finally, for those looking to network, we’ll wrap up with drinks and an opportunity to connect with like-minded professionals.   Don’t miss out on this event and use the registration link below to sign up.   https://lnkd.in/esu5-jTX   Thanks to Kate Fynes, Lindsey Clarke, and Nicola Ambler for making this event possible!

ISCT, International Society for Cell & Gene Therapy Europe 2024 kicked off yesterday providing brilliant presentations such as yesterday’s insightful plenary session on "Next Generation Cell Therapies: Enhancing Cell Potential to Advance Medicine.". Being co-chaired by Lindsay Davies, (NextCell Pharma AB) and Fermin Sanchez-Guijo, MD, PhD (University Hospital of Salamanca), the session provided an overview on current strategies being used to establish cells with improved characteristics to develop the next generation of cell-based therapies.   Thank you to those who joined bioMérieux’s corporate lunch session earlier today, where André Soares presented "How to streamline your CAR T therapy faster to the clinic: from development to cGMP manufacturing and beyond." It was an excellent opportunity to dive deep into CAR T development and quality control and explore strategies to reduce time and costs of these therapies. Thanks again to bioMérieux Pharma Quality Control for the opportunity to present!   Our team is eagerly engaging in interesting conversations at our booth and during the poster sessions, where the latest developments in the field of Cell & Gene Therapies are being presented. Make sure to connect with André & Sophia Kolbe during the rest of the conference — let's discuss how NecstGen can help accelerate your cell and gene therapy projects!   #ISCTEurope2024 #celltherapy #genetherapy #CGT

Join us for a corporate lunch session hosted by bioMérieux at ISCT, International Society for Cell & Gene Therapy Europe 2024 on September 5th, 12:30 PM. The session, titled "How to Streamline Your CAR T Therapy Faster to the Clinic: From Development to cGMP Manufacturing and Beyond," will focus on addressing challenges and opportunities in CAR T cell manufacturing.   With six therapies already approved by the EMA, CAR T therapies are the most successful cellular therapies to date. However, these therapies face multiple challenges, including cost and related patient access. This session will delve into the CAR T cell landscape and discuss strategies for process development to translate a research-grade process into a GMP-compliant manufacturing method.   With a unique mission of challenging the COGS of these therapies, NecstGen partners with cutting-edge technology developers, such as bioMérieux, to adopt their state-of-the-art technologies, that can ultimately help to reduce the manufacturing time and costs of Cell and Gene Therapies.   André Soares will speak on behalf of NecstGen, sharing valuable insights into how these collaborations pave the way for more efficient and accessible CAR T therapies.   Key Takeaways: Understanding the current and future landscape of CAR T cell therapies. Strategies for advancing CAR T therapies from concept to clinic. The critical role of Quality Control in clinical timelines. How NecstGen and bioMérieux are working together to streamline CAR T therapy development.   This session is open to all ISCT Europe 2024 attendees. We look forward to your participation and visit to our booth F01.42!

Yesterday, Sophia Kolbe and André Soares participated in a dynamic workshop at NecstGen, hosted in collaboration with RegMed XB.   The two-day workshop aims to deepen the participants’ understanding of business development strategies and sharpen our skills in effectively communicating and pitching our value. This workshop is bringing together the business developers of RegMed‘s pilot facilities Leiden University Medical Center, ReGEN Biomedical, ICAT, Smart BioMaterials Consortium (SBMC) and NecstGen. It creates a collaborative environment where we share ideas and insights on how to present our complementary ecosystem enabling regenerative medicine developers.    The workshop is led by Martin Bakker providing informative content and fostering interaction between the RegMed XB pilot facilities. Yesterday‘s workshop day was highlighted by the engaging pitch training held by guest speaker Joep van den Eerenbeemt focusing on how to powerfully connect and use mind, body, and voice when pitching.   Communication ensures the support we can offer to therapy developers as a non-profit pilot factory is clear in a busy and dynamic world. Supporting therapy developers helps more therapies reaching patients in need. #regmedxb #regenerativemedicine

We are excited to share that EUR 10 million have been awarded to NecstGen, NTrans Technologies BV, Leiden University Medical Center, and Divvly to transform Cell and Gene Therapies through the IPCEI Med4Health program. This significant funding will drive our efforts to transform the production of cell and gene therapies, making these life-saving treatments more accessible and affordable for patients in need.   The project will focus on developing innovative technologies and processes to overcome current manufacturing challenges, particularly on diseases like Duchenne Muscular Dystrophy and Diamond Blackfan Anemia. By streamlining production, we aim to reduce costs and facilitate the progression of these therapies into clinical trials. “By uniting our strengths and challenging current paradigms in Cell and Gene Therapy manufacturing, we can accelerate the availability of these life-saving therapies,” said Paul Bilars, Chief Executive Officer, NecstGen. “At NecstGen, we are dedicated to transforming these technologies to support therapy developers and ultimately, deliver life-changing treatments to patients, both in Europe and globally.” Read more about this collaborative effort and its impact here: https://lnkd.in/eaURZiu3 #celltherapy #genetherapy #biotechinnovation #IPCEI

We are excited to share that EUR 10 million have been awarded to NecstGen, NTrans Technologies BV, Leiden University Medical Center, and Divvly to transform Cell and Gene Therapies through the IPCEI Med4Health program. This significant funding will drive our efforts to transform the production of cell and gene therapies, making these life-saving treatments more accessible and affordable for patients in need.   The project will focus on developing innovative technologies and processes to overcome current manufacturing challenges, particularly on diseases like Duchenne Muscular Dystrophy and Diamond Blackfan Anemia. By streamlining production, we aim to reduce costs and facilitate the progression of these therapies into clinical trials. “By uniting our strengths and challenging current paradigms in Cell and Gene Therapy manufacturing, we can accelerate the availability of these life-saving therapies,” said Paul Bilars, Chief Executive Officer, NecstGen. “At NecstGen, we are dedicated to transforming these technologies to support therapy developers and ultimately, deliver life-changing treatments to patients, both in Europe and globally.” Read more about this collaborative effort and its impact here: https://lnkd.in/eaURZiu3 #celltherapy #genetherapy #biotechinnovation #IPCEI

We're #hiring a new Scientist Cell Therapy in Leiden, South Holland. Apply today or share this post with your network.

Meet us in Gothenburg, Sweden, from September 4 to 6 at booth #F01.42! We will attend the ISCT Europe 2024 Regional Meeting at the Swedish Exhibition & Congress Centre. This event will gather the brightest minds in Cell and Gene Therapy, offering a deep dive into our field's latest advancements, regulatory updates, and clinical applications. The ISCT, International Society for Cell & Gene Therapy Europe 2024 Regional Meeting is a key event for professionals dedicated to pushing the boundaries of Cell and Gene Therapy. With a program full of plenary sessions, hands-on workshops, and extensive networking opportunities, it's the place to be for anyone committed to innovation and collaboration in CGT. Committed to making a difference, NecstGen operates beyond profit motives. We aim to empower therapy developers with affordable, accessible, and state-of-the-art development and manufacturing services. Will we see you in Gothenburg? Connect with our team members, Sophia Kolbe and André Soares, to discuss how we can help accelerate your project and make a lasting impact together. You can use this link to schedule a meeting: https://lnkd.in/eYJ9VA9g #iscteurope2024 #celltherapy #genetherapy #regenerativemedicine #cgts